Document Detail

Bilateral mammary artery surgery or percutaneous transluminal coronary angioplasty for multivessel coronary artery disease? An analysis of effects and costs.
MedLine Citation:
PMID:  2516807     Owner:  NLM     Status:  MEDLINE    
Seventy-two patients with stable or unstable angina treated since 1983 by multivessel-PTCA(MVP) were retrospectively compared with 44 similar patients that were suitable for MVP, but who had undergone bilateral mammary artery (BIMA) surgery (and additional vein grafts in 60.5% of the patients) since 1986. Both groups were comparable (P = not significant [NS]) for gender, age, most risk factors, objective ischaemia and left ventricular function; however, in the BIMA group there were more previous infarctions (P = 0.02), hypertension (P = 0.03), three-vessel disease (P = 0.0001), and less severe angina (P = 0.007). In the BIMA group, a mean of 3.1 (range 2-5) vessels were treated and in the MVP group 2.0 (range 2-3) vessels (P = 0.0001). Both groups were almost completely revascularized (NS). In 39.5% of the BIMA group, no veins were used and in 20.9% the BIMAs were used as sequential grafts. In-hospital mortality was comparable: 2.3% for BIMA and 1.4% for MVP, so were periprocedural infarctions (13.6% vs 8.3%), rethoracotomies (9.1% vs 0%), emergency procedures (0% vs 5.7%), low cardiac output (2.3% vs 5.6%) and other complications (18.2% vs 9.2%). The mean stay (days) on the ICU/CCU for BIMA was 2.3 and for MVP 1.6 (P = 0.005) and the mean hospital stay for BIMA 12.3 and for MVP 6.6 (P = 0.0001). The maximum and mean follow-up (months) of 43 BIMA and 71 MVP hospital survivors was 35 vs 72 and 9.5 vs 22.3 (P = 0.0001) with a late mortality of 0% and 4.2% (NS). MVP patients, including 12 with re-procedures, had more recurrent angina (17.7% vs 4.7%, P less than 0.05) and more often used anti-anginal medications (62.0% vs 18.6%, P less than 0.0001). Late complications (excluding re-procedures) were comparable for MVP and BIMA (20% vs 9.3%, 4.4% vs 0%, 9.2% vs 14%). MVP patients had more re-hospitalizations (34 vs 5, P less than 0.0001), re-catheterizations (33% vs 2.3%, P less than 0.0001) and cardiac re-procedures (16 vs 0, P = 0.0006) than BIMA patients. Recurrent-angina-free survival at 1 year was 96% after BIMA and 64% after MVP (P less than 0.01). Event-free survival at 1 year was 86% after BIMA and 58% after MVP (P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)
E Berreklouw; J Hoogsteen; R van Wandelen; M Verkroost; J Schonberger; H Bavinck; R Michels; H Bonnier; M el Deeb; M el Gamal
Related Documents :
12218947 - Contemporary coronary intervention in bifurcation lesions--two-year follow-up in an uns...
10456827 - Audit and quality control in angioplasty in europe: procedural results of the aqua stud...
16049587 - A two-year, single-group experience with rotational atherectomy.
1571987 - Magnum system for routine coronary angioplasty: a randomized study.
2584547 - Long-term benefit of early thrombolytic therapy in patients with acute myocardial infar...
11446537 - Cardiac arrest management.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  European heart journal     Volume:  10 Suppl H     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1989 Dec 
Date Detail:
Created Date:  1990-04-24     Completed Date:  1990-04-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  61-70     Citation Subset:  IM    
Catharina Hospital, Department of Cardiopulmonary surgery, Eindhoven, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary* / economics
Coronary Disease / mortality,  pathology,  surgery,  therapy*
Coronary Vessels / pathology
Cost-Benefit Analysis
Follow-Up Studies
Internal Mammary-Coronary Artery Anastomosis* / economics
Middle Aged
Retrospective Studies
Survival Rate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Modern trends in monitoring in anaesthesia: its benefits and costs.
Next Document:  Renal failure in myelomatosis.